Signage is displayed outside Gilead Sciences Inc. headquarters in in Foster City, California, U.S., on Thursday, March 19, 2020. Gilead Sciences stock jumped as much as 7% on Thursday, reaching a two-year high, as a Piper Sandler analyst doubled down on his call on the approval prospects for the biotech company's experimental therapy for the pandemic now sweeping the U.S. Photographer: David Paul Morris/Bloomberg via Getty Images

Coronavirus Treatment Developed by Gilead Sciences Granted “Rare Disease” Status, Potentially Limiting Affordability

A promising anti-viral developed by Gilead Sciences, remdesivir, has received lucrative “orphan” drug status.

The Intercept